Work

Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2525

Authors: Manuel Hidalgo, Christophe Le Tourneau, Christophe Massard, Valentina Boni, Emiliano Calvo, Joan Albanell, Alvaro Taus, Marie-Paule Sablin, Andrea Varga, Ratislav Bahleda, Oliver Krieter, Lada Markovtsova, David Carlile, Angelika Lahr, Tapan Nayak, Katharina Lechner, Astrid Koehler, Ingrid Van Uffelen, Maria Martinez Garcia

Institutions: Institut Curie, Institut Gustave Roussy, Hospital Del Mar, F. Hoffmann-La Roche AG, Roche (United Kingdom)

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597469101

Cites:

Cited by: 14

Related to: 10